NorthWest Biotherapeutics Inc (NWBO)

[QL300]

Something is going on behind the scenes that is larger than NICE reimbursement. The last annual report mentioned that future employment agreements may have payments triggered by a change of control or the termination of a NEO. LP mentioned increasing the management team, restarting direct, building up manufacturing and starting the pediatric trial. They didn’t sign the deal with Roswell to sit on the tech. All these things cost money that we know NWBO doesn’t have. The cherry on top is NICE approval, or lack thereof. The MAA approval is huge but it not because of NICE revenue. LP doesn’t plan to pay for all of this by diluting at .40 a share. I’m convinced there is going to a large influx of cash shortly after approval.